Publications by authors named "Jonathan Priantti"

Claim this Profile
E
Efficacy and safety of RET-kinase inhibitors in RET-altered thyroid cancers: a systematic review and single-arm meta-analysis.
Israt Jahan Riya, Ifrat Jahan Piya, Jonathan N Priantti, Cha Len Lee, Lina Barman

Endocr Relat Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis.
Isabella Michelon, Maria Inez Dacoregio, Maysa Vilbert, Jonathan Priantti, Caio Ernesto do Rego Castro

Ther Adv Med Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.
Jonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, Isabella Michelon, Caio Castro

JCO Precis Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
Jonathan N Priantti, Natasha Maranhão Vieira Rodrigues, Francisco Cezar Aquino de Moraes, Allyson Guimarães da Costa, Deborah Laredo Jezini

Endocrine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Francisco Cezar Aquino de Moraes, Anna Luíza Soares de Oliveira Rodrigues, Jonathan N Priantti, Jhonny Limachi-Choque, Rommel Mario Rodríguez Burbano

J Gastrointest Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Jonathan N Priantti, Maysa Vilbert, Francisco Cezar Aquino de Moraes, Thiago Madeira, Evair Moisés de Lima Santiago

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials.
Francisco Cezar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N Priantti, Giovanna da Conceição Gomes

J Pers Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenchymal-Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis.
Francisco Cezar Aquino de Moraes, Maysa Vilbert, Vinícius Freire Costa Alves, Gustavo de Oliveira Almeida, Jonathan N Priantti

Int J Mol Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis.
Jonathan N Priantti, Maysa Vilbert, Thiago Madeira, Francisco Cezar A Moraes, Erica C Koch Hein

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis